Amneal Pharmaceuticals Inc. (AMRX) valuation against sector peers: P/E 40.9 (sector median 29.2), P/B 194.8, EV/EBIT 19.8, free-cash-flow yield 2.0%, P/S 2.1.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	AMRX	Sector median	vs median
P/E	40.9	29.2 · n=157	40% above
P/B	194.8	3.8 · n=307	5,007% above
P/S	2.1	4.1 · n=300	49% below
EV/EBIT	19.8	25.6 · n=145	23% below
Free-cash-flow yield	2.0%	1.5% · n=289	34% above
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	—	−2.4% · n=306	—
Return on invested capital	18.7%	0.6% · n=280	2,798% above
Gross margin	39.3%	63.3% · n=205	38% below
Net debt / EBITDA	—	1.30 · n=150	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Value factor: 60 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	46.2	31.6	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	41.3	8.2	—	3.1%	1.9%	8/10
ABBVAbbVie	50.0	—	27.6	3.7%	2.9%	6/10
MRKMerck	147.5	8.1	—	4.1%	2.3%	8/10
UNHUnitedHealth	22.2	3.4	16.9	6.5%	2.3%	10/10
TMOThermo Fisher Scientific	36.4	4.7	34.5	3.0%	0.3%	9/10
AMGNAmgen	26.5	17.4	23.0	3.8%	2.2%	8/10
GILDGilead Sciences	—	15.9	—	6.7%	1.9%	4/10
ABTAbbott	40.5	3.7	32.8	3.5%	2.8%	6/10
PFEPfizer	41.5	1.9	—	7.0%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 06 Aug 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings